Valeo Pharma Inc. VPHIF
0.00 USD 0.00 (+0.00%)
Regular-session close
0.1181 Day range 0.1181
0.0001 52-week range 0.1181
- YTD
- 0.00%
- 1 year
- -66.67%
News
proactiveinvestors.com Valeo Pharma adds chief development officer to drive growth initiatives Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) announced that Al Moghaddam will be taking up the newly created role of chief development officer and, as a result will be stepping down from the company's…
proactiveinvestors.com Valeo Pharma sees record 2Q revenue boosted by respiratory products and core brand growth Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) saw revenue for the second quarter of 2024 increase primarily driven by successful promotional activities for respiratory products, increased sales of…
proactiveinvestors.com Valeo Pharma restructures field operations to save over $5m annually Valeo Pharma Inc said it has launched a restructuring of its field sales operations, taking cost-cutting to more than $7 million a year, including other recent measures. The latest initiative, which…
proactiveinvestors.com Valeo Pharma taps life sciences leader for board position Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has announced the appointment of Al Moghaddam to its board of directors. The Kirkland, Quebec-based pharmaceutical company highlighted that Moghaddam brings…
proactiveinvestors.com Valeo Pharma sees 1Q revenue increase on strong performance from respiratory division Canadian pharmaceutical company Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) reported a 3% increase in first quarter revenue compared to the same period in the previous year driven by strong sales from…
proactiveinvestors.com Valeo Pharma unveils boardroom reshuffle Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) announced a boardroom reshuffle that includes the addition of two new members and the departure of four. Robert Raich and Charles Bisaillon have joined as…
proactiveinvestors.com Valeo Pharma amends Novartis eye treatment distribution agreement Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has unveiled changes to a seven-year agreement with Novartis Pharmaceuticals for the distribution of its eye treatment. Xiidra, a treatment for dry eye, will…
proactiveinvestors.com Valeo Pharma achieves record revenues for fiscal 2023 Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported record revenues of $54 million for fiscal 2023, representing a 94% year-over-year increase driven by increased demand for its prescription…
proactiveinvestors.com Valeo Pharma announces cost-reduction initiatives as it welcomes new CFO Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) told investors it expects to cut its operating expenses by more than $2 million a year by streamlining its organizational structure and commercial support…
proactiveinvestors.com Valeo Pharma welcomes Richard Lajoie to board of directors Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said Richard Lajoie has joined its board of directors while Maureen C. Brennan has retired from the board.
proactiveinvestors.com Valeo Pharma CEO credits Enerzair for strong position on Canada's top-growing companies list Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) CEO Steve Saviuk joined Proactive's Stephen Gunnion to discuss the company's strong position on the Globe and Mail's Report on Business annual list of…
proactiveinvestors.com Valeo Pharma secures spot on Canada's top-growing companies list Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) highlighted to investors that it has placed at spot 151 on the Globe and Mail's Report on Business annual list of Canada's top-growing companies. The company…
proactiveinvestors.com Valeo Pharma secures $5M credit facility agreement with Accord Financial Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) told investors it has entered into a $5 million credit facility with Accord Financial (TSX:ACD) which it said provides it with additional financial liquidity…
proactiveinvestors.com Valeo Pharma reports record quarterly revenue or strong demand for Enerzair and Atectura therapies Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported its seventh consecutive rise in revenues to a quarterly record due to strong growth in its Enerzair and Atectura asthma therapies. The Canadian…
proactiveinvestors.com Valeo Pharma raises funds totalling $4.5M Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has closed a non-brokered private placement offering, raising gross proceeds of $3.92 million. The company also secured a loan agreement with a related party…
proactiveinvestors.com Valeo Pharma bolsters board with two new directors Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said Tamara Close and Didier Leconte have both joined its board of directors, noting that following the appointments, Valeo's board now comprises of eight…
proactiveinvestors.com Valeo Pharma reports record quarterly revenues Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported record quarterly revenues of $13.6 million for its second quarter ending April 30, 2023, representing a substantial increase of 184% compared to…
proactiveinvestors.com Valeo Pharma expects 2Q revenues to set quarterly record Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said it expects revenues in the second quarter to exceed $13.5 million, a quarterly record, with operating expenses seen remaining in line with previous…
proactiveinvestors.com Valeo Pharma reports record 1Q revenue and gross profit buoyed by new products and higher market share Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said its revenue for the first quarter ended January 31, 2023, rose by 210% to a record $13.2 million, up from $4.2 million in the corresponding period of…
proactiveinvestors.com Valeo Pharma obtains public reimbursement for Onstryv in Quebec expanding access to the drug for Parkinson's patients Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said Onstryv (safinamide) for the treatment of patients with Parkinson's disease is now listed for reimbursement on the Public Prescription Drug Insurance…
